RET and colon adenocarcinoma: Lastly, when we examined the RET fusion-positive colon adenocarcinoma cohort, we observed a higher frequency of RNF43, MLL2, CASP8, CREBBP, BCORL1, SPEN, SMARCA4, BRCA2, MSH3, PTCH1, QKI, EP300, LRP1B, CDH1, and FANCA; but a lower frequency of APC, KRAS, PIK3CA, and BRAF genomic alterations when compared to the RET fusion-negative colon adenocarcinoma cohort (P < 0.05; Supplementary Table 9).